CME, NEX Set to Clear Final Acquisition Hurdles

The two firms are moving quickly to complete their tie-up after UK antitrust regulators give the green light.

london-st-pauls-1

Antitrust regulators in the UK have cleared the Chicago Mercantile Exchange Group’s (CME’s) acquisition of London-based NEX Group, paving the way for the two firms to form a significant force in global derivatives trading.

The CME is planning a share-and-cash acquisition of NEX, which was formed after interdealer broker Icap sold its voice-broking business to Tullett Prebon in 2016. NEX operates a number of electronic markets in currency and fixed-income trading, as well as a technology arm

Only users who have a paid subscription or are part of a corporate subscription are able to print or copy content.

To access these options, along with all other subscription benefits, please contact info@waterstechnology.com or view our subscription options here: http://subscriptions.waterstechnology.com/subscribe

You are currently unable to copy this content. Please contact info@waterstechnology.com to find out more.

Sorry, our subscription options are not loading right now

Please try again later. Get in touch with our customer services team if this issue persists.

New to Waterstechnology? View our subscription options

Register for free

Access two articles, our IMD and Waters Wraps, plus a member newsletter. Find out more.

All fields are mandatory unless otherwise highlighted.

This address will be used to create your account

This Week: What is going on?

Is it weird that Euronext bought Substantive? It’s weird, right? Plus WFIC, tick sizes, Microsoft and BlackRock want more datacenters for some reason, and, of course, AI. What does it all mean?

Why can’t we be friends?

The ABA vs most every regulator. LSEG vs BBG. AI vs SaaS. Buy vs build. Lots of drama in the capital markets.

Most read articles loading...

You need to sign in to use this feature. If you don’t have a WatersTechnology account, please register for a trial.

Sign in
You are currently on corporate access.

To use this feature you will need an individual account. If you have one already please sign in.

Sign in.

Alternatively you can request an individual account here